Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines
CompanyDeals

Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines

Innorna's IN013 Receives FDA Rare Pediatric Designation for Wilson's Disease Treatment
CompanyDrug

Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment

Amoytop Biotech to Acquire Skyline Therapeutics' Gene Therapy Assets for $15M Plus Milestones
CompanyDeals

Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones

Novo Nordisk's Emerging Business Division VP Eva Jiang Departs for External Opportunities
Company

Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities

Joyo Pharma's JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials
CompanyDrug

Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials

Zhejiang Huahai Pharma's HB0056 Receives NMPA Approval for Asthma Trials
CompanyDrug

Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials

Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer's Disease
CompanyDrug

Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease

Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights
CompanyDeals

Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights

Coherent Biopharma's CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer
CompanyDrug

Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer

Sanofi and Teva's Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
CompanyDrug

Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress

Triastek's 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy
CompanyDrug

Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy

J&J's Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
CompanyDrug

J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction